申请人:Pfizer Inc.
公开号:US05008263A1
公开(公告)日:1991-04-16
Platelet activating factor antagonists of formula (I), (II) or (III): ##STR1## where A is optionally substituted benzene, pyridine, naphthalene, quinoline, thiophene, benzothiophene, pyrazole or isothiazole, X is O, S or NH Y is 1,4 phenylene or a group of formula ##STR2## R.sup.1 is H or optionally substituted C.sub.1 -C.sub.4 alkyl, R.sup.2 and R.sup.3 are H or C.sub.1 -C.sub.4 alkyl, B is an optionally fused 5- or 6-membered ring containing nitrogen atoms, Het is an optionally substituted 5-membered heterocyclic ring containing nitrogen or a pyridine ring, the ring optionally being fused to benzene or nitrogen-containing heterocyclic ring.
式(I)、(II)或(III)的血小板活化因子拮抗剂:##STR1## 其中,A是可选取代的苯、吡啶、萘、喹啉、噻吩、苯并噻吩、吡唑或异噻唑;X是O、S或NH;Y是1,4-苯撑基或公式##STR2##的基团;R.sup.1是H或可选取代的C.sub.1-C.sub.4烷基;R.sup.2和R.sup.3是H或C.sub.1-C.sub.4烷基;B是可选的含氮5-或6-元环,Het是可选取代的含氮5-元杂环或吡啶环,该环可选择与苯或含氮杂环环融合。